Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (2040)	1/16/2000 11:22:00 AM
From: Mad2	Read Replies (1) \| Respond to of 5582

Mad2: I would appreciate hearing your reasons for thinking that Pleconaril could be bad news for Zicam next cold season Dan this is what I wrote WLA's Agouron's division and Pleconaril that appear to target rhinovirus infection as well as other documented viral infections. How do you figure this is benificial for Zicam. From a longer range view, ie next cold season this might even be harmful. I'd agree that at $50-100 bucks a dose the Pleconaril seems to be shooting for a segment above the "common cold". However my thought was more along the lines of where WLA's Agournon divison is headed.... Mad2